This site is intended for healthcare professionals

Eisai Co., Ltd. has submitted a marketing authorization application in Japan for the EZH2 inhibitor tazemetostat hydrobromide for EZH2 gene mutation-positive follicular lymphoma.

Read time: 1 mins
Last updated:16th Mar 2021
Published:10th Jul 2020
Condition: Follicular Lymphoma
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest